Subject: A survey among dermatologists to understand usage pattern of tofacitinib in autoimmune dermatological conditions in India
Tofacitinib citrate is an oral Janus kinase (JAK) 1/3 inhibitor initially approved for rheumatoid arthritis in 2012. Within the field of dermatology, off-label trials of tofacitinib have been reported for various inflammatory and other conditions involving cell types that are heavily regulated by JAK1/3, such as psoriasis, alopecia areata, and atopic dermatitis (AD). Moreover, DCGI- approved topical tofacitinib 2% for mild-moderate AD in patients of 18 years & above having flares up of disease. There are currently a multitude of reported and active clinical trials utilizing tofacitinib for skin disorders.
This survey is conducted among dermatologists to understand usage pattern of tofacitinib in autoimmune dermatological conditions in India.
As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of Rs {{$contractAmount}}, on receiving the completed Survey Questionnaire Form from you.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})